Serious. I don't think YMI is a 'quasi-legit scam company.'
Nimotuzumab has considerable promise, particularly given the recent demonstration that EGFRs are effective upfront for mCRC. Provided equivalent efficacy, nimo has the potential to completely supplant cetuximab because of the side-effect profile.
As always, I only care where YMI is going to be 6 mo to 1 y down the road. If I can get this at or near cash, then I'm in.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.